CompletedNot Applicable

Post-Traumatic Growth Following Eye Movement Desensitization and Reprocessing Therapy Versus SSRIs in Patients With Post-Traumatic Stress Disorder

Pakistan130 participantsStarted 2025-05-06

Plain-language summary

This randomized controlled trial investigates the comparative effectiveness of Eye Movement Desensitization and Reprocessing (EMDR) therapy and selective serotonin reuptake inhibitors (SSRIs) in fostering post-traumatic growth among patients diagnosed with post-traumatic stress disorder (PTSD). Participants will be randomized to receive either EMDR therapy or standard SSRI pharmacotherapy. The primary objective is to evaluate the extent of psychological growth and recovery achieved through each intervention, aiming to guide future therapeutic strategies for PTSD.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: Clinical diagnosis of Post-Traumatic Stress Disorder (PTSD) based on DSM-5 criteria Willingness to participate and provide informed consent Ability to comply with study procedures Exclusion Criteria: Current diagnosis of psychotic disorder, bipolar disorder, or severe major depressive episode with psychotic features Active substance use disorder within the past 6 months Severe cognitive impairment or inability to complete study assessments

What they're measuring

Post-Traumatic Growth (PTG) measured by Post-Traumatic Growth Inventory (PTGI)

Timeframe: 6 weeks

Trial details

NCT IDNCT06957210

SponsorAsad Ullah Jan

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-11-30

View on ClinicalTrials.gov More PTSD - Post Traumatic Stress Disorder trials